Flávia Sousa

Dr. Flávia Sousa

Istituto Italiano di Tecnologia (IIT), Genova.
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2017 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDF file
CMCláudia Martins
Cláudia Martins
Flávia SousaFlávia Sousa
Flávia Sousa
FAFrancisca Araújo
Francisca Araújo
Bruno SarmentoBruno Sarmento
Bruno Sarmento
Poly(lactic‐co‐glycolic) acid (PLGA) is one of the most versatile biomedical polymers, already approved by regulatory authorities to be used in human research and clinics. Due to its valuable characteristics, PLGA can be tailored to acquire desirable features for control bioactive payload or scaffold matrix. Moreover, its chemical modification with other polymers or bioconjugation with molecules may render PLGA with functional properties that make it the Holy Grail among the synthetic polymers to be applied in the biomedical field. In this review, the physical–chemical properties of PLGA, its synthesis, degradation, and conjugation with other polymers or molecules are revised in detail, as well as its applications in drug delivery and regeneration fields. A particular focus is given to successful examples of products already on the market or at the late stages of trials, reinforcing the potential of this polymer in the biomedical field.

1 December 2020 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
JFJoel A. Finbloom
Joel A. Finbloom
Flávia SousaFlávia Sousa
Flávia Sousa
MSMolly M. Stevens
Molly M. Stevens
TDTejal A Desai
Tejal A Desai

1 September 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
Flávia SousaFlávia Sousa
Flávia Sousa
HDHarkiranpreet Kaur Dhaliwal
Harkiranpreet Kaur Dhaliwal
FGFlorence Gattacceca
Florence Gattacceca
Bruno SarmentoBruno Sarmento
Bruno Sarmento
Mansoor M. AmijiMansoor M. Amiji
Mansoor M. Amiji

5 March 2020 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
JMJoão Pedro Martins
João Pedro Martins
JNJosé das Neves
José das Neves
MFMaría de la Fuente
María de la Fuente
Christian CeliaChristian Celia
Christian Celia
HFHelena Florindo
Helena Florindo
Hélder SantosHélder Santos
Hélder Santos
This commentary article conveys the views of the board of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society regarding the decision of the United States National Cancer Institute (NCI) in halting funding for the Centers of Cancer Nanotechnology Excellence (CCNEs), and the subsequent editorial articles that broadened this discussion.

26 February 2019 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
RMRui Pedro Moura
Rui Pedro Moura
CMCláudia Martins
Cláudia Martins
SPSoraia Pinto
Soraia Pinto
Flávia SousaFlávia Sousa
Flávia Sousa
Bruno SarmentoBruno Sarmento
Bruno Sarmento
Introduction: The blood-brain barrier (BBB) is a highly limiting barrier that prevents the brain from contacting with several circulating molecules, including harmful agents. However, certain systemic nutrients and macromolecules are able to cross the BBB and reach the brain parenchyma, involving the interaction with multiple receptors and/or transporters at BBB surface. Nanotechnology allows the creation of drug vehicles, functionalized with targeting ligands for binding specific BBB receptors and/or transporters, hence triggering the transport through this biobarrier. Areas covered: This review focus the BBB receptors/transporters to be exploited in regard to their overall structure and biologic function, as well as their role in the development of strategies envisaging drug delivery to the brain. Then, the interplay between the targeting of these BBB receptors/transporters and nanotechnology is explored, as they can increase by several-fold the effectiveness of brain-targeted therapies. Expert opinion: Nanomedicine may be particularly useful in brain drug delivery, mainly due to the possibility of functionalizing nanoparticles to target specific receptors/transporters. Since the BBB is endowed with numerous receptors and transporters responsible for regulating the proper metabolic activity of the brain, their targeting can be a promising bypass strategy to circumvent the hurdle that the BBB represents for brain drug delivery.

16 June 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Flávia SousaFlávia Sousa
Flávia Sousa
ACAndrea Cruz
Andrea Cruz
Pedro FontePedro Fonte
Pedro Fonte
IMInês Pinto Mendes-Pinto
Inês Pinto Mendes-Pinto
MNMaria Teresa Neves-Petersen
Maria Teresa Neves-Petersen
Bruno SarmentoBruno Sarmento
Bruno Sarmento
Monoclonal antibodies have deserved a remarkable interest for more than 40 years as a vital tool for the treatment of various diseases. Still, there is a raising interest to develop advanced monoclonal antibody delivery systems able to tailor pharmacokinetics. Bevacizumab is a humanized immunoglobulin IgG1 used in antiangiogenic therapies due to its capacity to inhibit the interaction between vascular endothelial growth factor and its receptor. However, bevacizumab-based antiangiogenic therapy is not always effective due to poor treatment compliance associated to multiples administrations and drug resistance. In this work, we show a promising strategy of encapsulating bevacizumab to protect and deliver it, in a controlled manner, increasing the time between administrations and formulation shelf-life. Nanoencapsulation of bevacizumab represents a significant advance for selective antiangiogenic therapies since extracellular, cell surface and intracellular targets can be reached. The present study shows that bevacizumab-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles does not impair its native-like structure after encapsulation and fully retain the bioactivity, making this nanosystem a new paradigm for the improvement of angiogenic therapy.